Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Front Immunol · 2026 · PMC13233545 · PMID 42253973

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although no statistically significant differences were observed, early progressors at<week 26 showed a trend towards higher levels of CD137 + HLA-DR + CD4 + , CD4 + CTLA4 + , Tim3 + CTLA4 + CD4 + T cells, as well as neutrophils/PMN-MDSCs ( Supplementary Figures 8A–D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.